Home » Topics » Hematologic, BioWorld Science

Hematologic, BioWorld Science
RSS

Direct factor Xa inhibitor FXV-673 shows good results versus heparin

Nov. 21, 2000

Novel thrombin inhibitor prodrugs for oral administration

Nov. 20, 2000

Genzyme Transgenics reacquires rights to rhATIII

Nov. 17, 2000

SmithKline Beecham launches Argatroban in U.S.

Nov. 15, 2000

Soluble CD39: ex vivo dose-response evaluation in combination with known antiplatelet agents

Nov. 14, 2000

Venous and arterial antithrombotic effects described at AHA meeting for DPC-423

Nov. 14, 2000

Melagatran dose-dependently reduces platelet and fibrin deposition following angioplasty

Nov. 14, 2000

DuPont prepares aryl sulfonyl-based factor Xa inhibitors

Nov. 13, 2000

Novel series of anticoagulants patented by Kissei research team

Nov. 13, 2000

First potent and selective, nonpeptide thrombin receptor antagonists described by Schering-Plough

Nov. 9, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 5, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Axsome’s Auvelity cleared for large Alzheimer’s agitation market
BioWorld
Axsome Therapeutics Inc. won U.S. FDA approval for Auvelity (AXS-05) to treat Alzheimer’s disease agitation, a condition that affects up to three-quarters of...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Sonire starts US study of cancer HIFU after $18M series A
BioWorld
Sonire Therapeutics Inc. initiated a U.S.-based Sunrise II study of Suizenji, its novel ultrasound-guided high-intensity focused ultrasound (HIFU) system designed...